Table 3.
Results of regression analyses conducted for the electrocutaneous pain threshold and tolerance assessmenta
| Equation R2 | Predictor variable(s) | Beta | t-value | P |
|---|---|---|---|---|
| Electrocutaneous pain threshold | ||||
| 0.08 | Sex | 0.00 | 0.03 | ns |
| Drug | −0.12 | −1.19 | ns | |
| Catastrophizing | −0.26 | −2.50 | < 0.05 | |
| Electrocutaneous pain tolerance | ||||
| 0.08 | Sex | −0.20 | −1.87 | ns |
| Drug | −0.02 | −0.19 | ns | |
| Catastrophizing | −0.19 | −1.80 | ns | |
| Pain rating index of the short form of MPQ | ||||
| 0.21 | Sex | −0.13 | −1.34 | ns |
| Drug | −0.09 | −0.92 | ns | |
| Catastrophizing | 0.45 | 4.63 | < 0.001 | |
Predictor variables include sex (male = 0, female = 1), drug (naltrexone = 0, placebo = 1), and pain catastrophizing score.